Is Pexidartinib an immunosuppressant?

Pexidartinib is not an immunosuppressant. It is a targeted therapy drug that acts on certain specific molecules or signaling pathways to inhibit tumor growth and spread. Although pesidartinib is a targeted drug, it is not an immunotherapy. Immunotherapy usually refers to a type of treatment that uses the activation or enhancement of a patient's own immune system to fight cancer, such as immune checkpoint inhibitors, CAR-T cell therapy, etc.

Pesidartinib is the first effective targeted drug therapy to provide a systemic treatment option for advanced symptomatic tenosynovial giant cell tumors (TGCT) and is a potentially valuable alternative to surgery when surgical approaches may result in excessive morbidity. 12 Because the risks associated with this drug are well documented, the optimal period of use is unknown, and treatment courses are often prolonged, it is critical to identify patients who will derive the greatest benefit from its use and who have the risk of adverse events appropriately balanced by avoiding the alternative risks of surgery or observation. These predictions should be based on the patient's individual risk for severe postoperative morbidity, severity of disease at baseline, and comorbidities. As the TOPP study suggests, patient-specific factors and characteristics at baseline should be important considerations when determining treatment modalities.

Pesidartinib is not marketed in the country. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.